## Chester B Good

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9282711/publications.pdf

Version: 2024-02-01

		168829	1	75968	
125	3,506	31		55	
papers	citations	h-index		g-index	
			_		
129	129	129		5239	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	Citations
1	Identifying outcome measures for atrial fibrillation value-based contracting using the Delphi method. Research in Social and Administrative Pharmacy, 2022, 18, 3425-3431.	1.5	1
2	Real-World Use and Outcomes of Oral Antiplatelets Among Patients with Acute Coronary Syndrome: A Retrospective Cohort Study. Drugs - Real World Outcomes, 2022, 9, 121-127.	0.7	1
3	Twelve month oral contraceptive pill prescriptions: Role of policy mandates on utilization. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100094.	0.6	2
4	Impact of the COVID-19 pandemic on new starts to oral oncology medications in the US. Journal of Oncology Pharmacy Practice, 2022, , 107815522110737.	0.5	2
5	Patient and medicationâ€related factors associated with opioid use disorder after inpatient opioid administration. Journal of Hospital Medicine, 2022, 17, 342-349.	0.7	O
6	Economic assessment of changes to an existing medication therapy management program of a large regional health plan. Journal of Managed Care & Eamp; Specialty Pharmacy, 2021, 27, 147-156.	0.5	1
7	Impact of Marijuana Legalization on Opioid Utilization in Patients Diagnosed with Pain. Journal of General Internal Medicine, 2021, 36, 3417-3422.	1.3	3
8	Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014–2019. Medical Care, 2021, 59, 789-794.	1,1	11
9	Infection Incidence and Management in Multiple Sclerosis Patients After Initiating Disease-Modifying Therapy. Multiple Sclerosis and Related Disorders, 2021, 56, 103285.	0.9	2
10	Exploring behavioural factors affecting nutritional supplement use among children in Honduras. Public Health Nutrition, 2021, , 1-9.	1.1	0
11	Impact of direct-to-consumer drug advertising during the Super Bowl on drug utilization. Research in Social and Administrative Pharmacy, 2020, 16, 1136-1139.	1.5	2
12	Identifying Outcome Measures for Migraine Valueâ€Based Contracting Using the Delphi Method. Headache, 2020, 60, 2139-2151.	1.8	3
13	Interpreting COVID-19 Test Results: a Bayesian Approach. Journal of General Internal Medicine, 2020, 35, 2490-2491.	1.3	5
14	Disclosure of Article Funding and Conflicts of Interest in High-Impact Clinical Journals. Journal of General Internal Medicine, 2020, 35, 1345-1347.	1.3	0
15	Using the Delphi method to identify meaningful and feasible outcomes for pharmaceutical value-based contracting. Journal of Managed Care & Decialty Pharmacy, 2020, 26, 1385-1389.	0.5	1
16	Identifying sociodemographic profiles of veterans at risk for high-dose opioid prescribing using classification and regression trees. Journal of Opioid Management, 2020, 16, 409-424.	0.2	0
17	Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D. JAMA Neurology, 2019, 76, 1386.	4.5	29
18	Characteristics of Opioid Prescriptions to Veterans WithÂCirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 1165-1174.e3.	2.4	25

#	Article	IF	CITATIONS
19	Determination of Multiple Sclerosis Indicators for Value-Based Contracting Using the Delphi Method. Journal of Managed Care & Delphi Method. Journal of Managed Care & Delphi Method.	0.5	2
20	Use of a medication-based risk adjustment index to predict mortality among veterans dually-enrolled in VA and medicare. Healthcare, $2019, 7, \dots$	0.6	4
21	Identifying Outcome Measures for Type 2 Diabetes Value-Based Contracting Using the Delphi Method. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 324-331.	0.5	3
22	Identifying Outcome Measures for Coronary Artery Disease Value-Based Contracting Using the Delphi Method. Cardiology and Therapy, 2019, 8, 135-143.	1.1	7
23	Dual Receipt of Prescription Opioids From the Department of Veterans Affairs and Medicare Part D and Prescription Opioid Overdose Death Among Veterans. Annals of Internal Medicine, 2019, 170, 433.	2.0	25
24	Statins for Primary Prevention of Cardiovascular Disease. Annals of Internal Medicine, 2019, 171, 72.	2.0	2
25	Patterns of opioid prescriptions received prior to unintentional prescription opioid overdose death among Veterans. Research in Social and Administrative Pharmacy, 2019, 15, 1007-1013.	1.5	9
26	Characteristics of dual drug benefit use among veterans with dementia enrolled in the Veterans Health Administration and Medicare Part D. Research in Social and Administrative Pharmacy, 2019, 15, 701-709.	1.5	4
27	How the dual process model of human cognition can inform efforts to deâ€implement ineffective and harmful clinical practices: A preliminary model of unlearning and substitution. Journal of Evaluation in Clinical Practice, 2018, 24, 198-205.	0.9	82
28	Impact of Dual Use of Department of Veterans Affairs and Medicare Part D Drug Benefits on Potentially Unsafe Opioid Use. American Journal of Public Health, 2018, 108, 248-255.	1.5	53
29	Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study. Journal of General Internal Medicine, 2018, 33, 1253-1259.	1.3	27
30	Ethical Obligations Regarding Short-Term Global Health Clinical Experiences. Annals of Internal Medicine, 2018, 169, 588.	2.0	0
31	Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence. BMC Medicine, 2018, 16, 238.	2.3	2
32	Receipt of Overlapping Opioid and Benzodiazepine Prescriptions Among Veterans Dually Enrolled in Medicare Part D and the Department of Veterans Affairs. Annals of Internal Medicine, 2018, 169, 593.	2.0	27
33	Lowering the <i>P</i> Value Threshold. JAMA - Journal of the American Medical Association, 2018, 320, 935.	3.8	3
34	An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries. Health Policy, 2018, 122, 1012-1017.	1.4	6
35	Should Metformin Be First-line Therapy for Patients With Type 2 Diabetes and Chronic Kidney Disease?. JAMA Internal Medicine, 2018, 178, 911.	2.6	6
36	Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine. JAMA Internal Medicine, 2018, 178, 873.	2.6	0

3

#	Article	IF	CITATIONS
37	Industry Payments to Academic Physicians: a Comparison of Reporting to Two Government Agencies. Journal of General Internal Medicine, 2018, 33, 1604-1606.	1.3	5
38	Addressing the Opioid Epidemic in the United States. JAMA Internal Medicine, 2017, 177, 611.	2.6	171
39	Pharmacotherapy for Weight Management in the VHA. Journal of General Internal Medicine, 2017, 32, 70-73.	1.3	19
40	Dual Health Care System Use and High-Risk Prescribing in Patients With Dementia. Annals of Internal Medicine, 2017, 166, 157.	2.0	40
41	The Impact of Medication-Based Risk Adjustment on the Association Between Veteran Health Outcomes and Dual Health System Use. Journal of General Internal Medicine, 2017, 32, 967-973.	1.3	10
42	Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D. Substance Abuse, 2017, 38, 22-25.	1.1	26
43	Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 114-120.	0.5	11
44	Pharmacy Benefits Management in the Veterans Health Administration Revisited: A Decade of Advancements, 2004-2014. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1058-1063.	0.5	22
45	A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch. Addiction, 2016, 111, 1283-1292.	1.7	19
46	Prescription of Brand-Name Medications When Generic Alternatives Are Availableâ€"Patently Unfair. JAMA Internal Medicine, 2016, 176, 1323.	2.6	2
47	Costâ€effectiveness of new antiviral regimens for treatmentâ€naÃ⁻ve U.S. veterans with hepatitis C. Hepatology, 2016, 63, 428-436.	3.6	33
48	Drug alerts and the Goldilocks principle: Striving for "just right― American Journal of Health-System Pharmacy, 2016, 73, 517-517.	0.5	1
49	Provider Response to QTc Prolongation on Standard 12‣ead EKG: Do We Notice or Do We Care?. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1174-1180.	0.5	7
50	Association between opioid use and readmission following liver transplantation. Clinical Transplantation, 2016, 30, 1222-1229.	0.8	22
51	VA and Medicare Utilization Among Dually Enrolled Veterans with Type 2 Diabetes: A Latent Class Analysis. Journal of General Internal Medicine, 2016, 31, 524-531.	1.3	16
52	Finding the Balance of Less Is More. JAMA Internal Medicine, 2016, 176, 282.	2.6	0
53	Off-label Drug Use and Adverse Drug Events. JAMA Internal Medicine, 2016, 176, 63.	2.6	17
54	Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. PLoS ONE, 2016, 11, e0158017.	1.1	111

#	Article	IF	CITATIONS
55	Pre-Transplant Depression Is Associated with Length of Hospitalization, Discharge Disposition, and Survival after Liver Transplantation. PLoS ONE, 2016, 11, e0165517.	1.1	29
56	Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers. Oncology Research, 2015, 22, 311-319.	0.6	2
57	Prevalence and compensation of academic leaders, professors, and trustees on publicly traded US healthcare company boards of directors: cross sectional study. BMJ, The, 2015, 351, h4826.	3.0	19
58	Dual Use of Department of Veterans Affairs and Medicare Benefits and Use of Test Strips in Veterans With Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2015, 175, 26.	2.6	45
59	Tight Clycemic Control and Use of Hypoglycemic Medications in Older Veterans With Type 2 Diabetes and Comorbid Dementia. Diabetes Care, 2015, 38, 588-595.	4.3	104
60	Association of skeletal muscle relaxers and antihistamines on mortality, hospitalizations, and emergency department visits in elderly patients: a nationwide retrospective cohort study. BMC Geriatrics, 2015, 15, 2.	1.1	29
61	Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer, 2015, 15, 62.	1.1	69
62	The Association of Cardioprotective Medications with Pneumonia-Related Outcomes. PLoS ONE, 2014, 9, e85797.	1.1	24
63	An Ethical Framework for Pharmacy Management: Balancing Autonomy and Other Principles. Journal of Managed Care Pharmacy, 2014, 20, 334-338.	2.2	3
64	Academic Medical Center Leadership on Pharmaceutical Company Boards of Directors. JAMA - Journal of the American Medical Association, 2014, 311, 1353.	3.8	18
65	Association of Azithromycin With Mortality and Cardiovascular Events Among Older Patients Hospitalized With Pneumonia. JAMA - Journal of the American Medical Association, 2014, 311, 2199.	3.8	150
66	Decrease the Incentives to Order Lipid Panels. JAMA Internal Medicine, 2014, 174, 473.	2.6	1
67	Potential Conflicts of Interest for Academic Medical Center Leaders—Reply. JAMA - Journal of the American Medical Association, 2014, 312, 558.	3.8	1
68	New Cholesterol Guidelines: Has Godot Finally Arrived?. Annals of Internal Medicine, 2014, 160, 354-355.	2.0	15
69	Incremental Cost Effectiveness of Pharmacist-Managed Erythropoiesis-Stimulating Agent Clinics for Non-Dialysis-Dependent Chronic Kidney Disease Patients. Applied Health Economics and Health Policy, 2013, 11, 653-660.	1.0	12
70	Adherence to hormonal contraception among womenÂveterans: differences by race/ethnicity andÂcontraceptive supply. American Journal of Obstetrics and Gynecology, 2013, 209, 103.e1-103.e11.	0.7	25
71	The Quality of Quality Measures: HEDIS® Quality Measures for Medication Management in the Elderly and Outcomes Associated with New Exposure. Drugs and Aging, 2013, 30, 645-654.	1.3	21
72	Medication-use evaluation with a Web application. American Journal of Health-System Pharmacy, 2013, 70, 2226-2234.	0.5	13

#	Article	IF	CITATIONS
73	Topical Anesthetic-Induced Methemoglobinemia and Veterans Affairs Hospitals. JAMA Internal Medicine, 2013, 173, 2013.	2.6	1
74	Brand-Name Prescription Drug Use Among Veterans Affairs and Medicare Part D Patients With Diabetes. Annals of Internal Medicine, 2013, 159, 105-14.	2.0	30
75	Variation in Use of High-Cost Diabetes Mellitus Medications in the VA Healthcare System. Archives of Internal Medicine, 2012, 172, 1608.	4.3	14
76	Population-Based Study of Statins, Angiotensin II Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors on Pneumonia-Related Outcomes. Clinical Infectious Diseases, 2012, 55, 1466-1473.	2.9	137
77	Monitoring adverse drug reactions across a nationwide health care system using information technology. American Journal of Health-System Pharmacy, 2012, 69, 321-328.	0.5	17
78	Use of Antipsychotics Among Older Residents in VA Nursing Homes. Medical Care, 2012, 50, 954-960.	1.1	47
79	Impact of Pharmacist-Managed Erythropoiesis-Stimulating Agents Clinics for Patients With Non–Dialysis-Dependent CKD. American Journal of Kidney Diseases, 2012, 60, 371-379.	2.1	26
80	Glycemic Control Was Unchanged in Veterans Health Administration Patients Converted from Glyburide to Glipizide. Journal of Managed Care Pharmacy, 2012, 18, 73-73.	2.2	1
81	Facilityâ€Level Variation in Potentially Inappropriate Prescribing for Older Veterans. Journal of the American Geriatrics Society, 2012, 60, 1222-1229.	1.3	14
82	Incremental cost-effectiveness of various monthly doses of vardenafil. Value in Health, 2011, 14, 97-101.	0.1	5
83	Intervention to Decrease Glyburide Use in Elderly Patients With Renal Insufficiency. American Journal of Geriatric Pharmacotherapy, 2011, 9, 58-68.	3.0	26
84	Potential Safety Gaps in Order Entry and Automated Drug Alerts. Medical Care, 2011, 49, 904-910.	1.1	11
85	Trends in Use of Highâ€Risk Medications for Older Veterans: 2004 to 2006. Journal of the American Geriatrics Society, 2011, 59, 1891-1898.	1.3	27
86	Observational Study of Inhaled Corticosteroids on Outcomes for COPD Patients with Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 312-316.	2.5	83
87	Provision of Potentially Teratogenic Medications to Female Veterans of Childbearing Age. Medical Care, 2010, 48, 834-842.	1.1	31
88	Severe Dysglycemia with the Fluoroquinolones: A Class Effect?. Clinical Infectious Diseases, 2009, 49, 402-408.	2.9	81
89	Clinical Significance of Borderline Elevated Troponin I Levels Across Different Assays in Patients With Suspected Acute Coronary Syndrome. American Journal of Cardiology, 2009, 104, 164-168.	0.7	12
90	Antibiotic prescribing for presumed nonbacterial acute respiratory tract infections. American Journal of Emergency Medicine, 2009, 27, 544-551.	0.7	27

#	Article	IF	Citations
91	Prescription Drug Samples: Making Decisions with Imperfect Data. Journal of General Internal Medicine, 2008, 23, 890-892.	1.3	4
92	Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder. Journal of Affective Disorders, 2008, 107, 53-62.	2.0	106
93	Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: A cross-sectional study. Clinical Therapeutics, 2008, 30, 1135-1144.	1.1	22
94	Determinants of Hormone Therapy Discontinuation among Female Veterans Nationally. Military Medicine, 2008, 173, 91-96.	0.4	11
95	Evaluation of Clostridium difficile-Associated Diarrhea With a Drug Formulary Change in Preferred Fluoroquinolones. Journal of Managed Care Pharmacy, 2008, 14, 34-40.	2.2	14
96	Rate and predictors of treatment prescription for hepatitis C. Gut, 2007, 56, 385-389.	6.1	139
97	Access to Affordable Medications: The Department of Veterans Affairs Pharmacy Plan as a National Model. American Journal of Public Health, 2007, 97, 2129-2131.	1.5	15
98	Symptom Expression in Coronary Heart Disease and Revascularization Recommendations for Black and White Patients. American Journal of Public Health, 2007, 97, 1701-1708.	1.5	13
99	Understanding of the benefits of coronary revascularization procedures among patients who are offered such procedures. American Heart Journal, 2007, 154, 662-668.	1.2	48
100	Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. Journal of Affective Disorders, 2007, 102, 145-151.	2.0	73
101	Impact of Blood Transfusions in Patients Presenting With Anemia and Suspected Acute Coronary Syndrome. American Journal of Cardiology, 2007, 99, 1119-1121.	0.7	48
102	Comparison of Frequency of New-Onset Atrial Fibrillation or Flutter in Patients on Statins Versus Not on Statins Presenting With Suspected Acute Coronary Syndrome. American Journal of Cardiology, 2007, 100, 404-405.	0.7	43
103	Effect of Hyponatremia (<135 mEq/L) on Outcome in Patients With Non–ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2007, 100, 406-408.	0.7	40
104	Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clinical Cardiology, 2006, 29, 65-68.	0.7	41
105	Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium. Annals of Internal Medicine, 2006, 144, 147.	2.0	1
106	The Evolving Use of Cost-Effectiveness Analysis in Formulary Management Within the Department of Veterans Affairs. Medical Care, 2005, 43, Il-20.	1.1	26
107	Bleeding risk index in an anticoagulation clinic. Journal of General Internal Medicine, 2005, 20, 1008-1013.	1.3	41
108	Spiraling Drug Costs: A Call for Cost-Effective Prescribing. Journal of the American Geriatrics Society, 2005, 53, 1427-1429.	1.3	2

#	Article	IF	CITATIONS
109	Effect of both elevated troponin-I and peripheral white blood cell count on prognosis in patients with suspected myocardial injury. American Journal of Cardiology, 2005, 95, 970-972.	0.7	7
110	Perioperative Risk of Noncardiac Surgery Associated With Aortic Stenosis. American Journal of Cardiology, 2005, 96, 436-438.	0.7	57
111	Target Blood Pressure and Kidney Disease. Annals of Internal Medicine, 2005, 143, 310.	2.0	0
112	Racial Variations in Treatment and Outcomes of Black and White Patients With High-Risk Non–ST-Elevation Acute Coronary Syndromes. Circulation, 2005, 111, 1225-1232.	1.6	208
113	Racial Differences in the Treatment of Veterans With Bipolar Disorder. Psychiatric Services, 2005, 56, 1549-1555.	1.1	34
114	The Vioxx debacle revisited. American Journal of Medicine, 2005, 118, 1055-1056.	0.6	2
115	How Does Depression Influence Diabetes Medication Adherence in Older Patients?. American Journal of Geriatric Psychiatry, 2005, 13, 202-210.	0.6	84
116	Incidence and Severity of Potential Drug–Dietary Supplement Interactions in Primary Care Patients. Archives of Internal Medicine, 2004, 164, 630.	4.3	94
117	Racial/Ethnic Variations in Physician Recommendations for Cardiac Revascularization. American Journal of Public Health, 2003, 93, 1689-1693.	1.5	70
118	Equal Effectiveness of Older Traditional Antibiotics and Newer Broad-Spectrum Antibiotics in Treating Patients with Acute Exacerbations of Chronic Bronchitis. Southern Medical Journal, 2003, 96, 986-991.	0.3	14
119	Delay in Presentation for Cardiac Care by Race, Age, and Site of Care. Medical Care, 2002, 40, I-97-I-105.	1.1	17
120	Topical beta-blockers in patients with co-existing conditions: is this a cause for concern?. Pharmacoepidemiology and Drug Safety, 2001, 10, 509-510.	0.9	3
121	Update in Pulmonary Disease. Annals of Internal Medicine, 2001, 135, 301.	2.0	1
122	Understanding Racial Variation in the Use of Coronary Revascularization Procedures. Archives of Internal Medicine, 2000, 160, 1329.	4.3	101
123	Use of ice-water bag to obtain dive reflex. American Journal of Medicine, 1992, 93, 116.	0.6	2
124	Profound Papilledema Due to Cryptococcal Meningitis in Acquired Immunodeficiency Syndrome. Southern Medical Journal, 1991, 84, 394-395.	0.3	3
125	Pericardial Effusion and Tamponade due to Kaposi's Sarcoma in Acquired Immunodeficiency Syndrome. Chest, 1989, 95, 1359-1361.	0.4	67